Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/33276
Title: The incretin abc's in helath and disease-novel approaches to obesity and diabetes treatment
Authors: João, Ana Luísa de Natividade Faria 
Orientador: Fernandes, Rosa Cristina Simões
Reis, Flávio Nelson Fernandes
Keywords: Incretin-based therapies; Glucagon-like peptide-1 (GLP-1); Dipeptidyl peptidase-4 (DPP-4); Obesity; Type 2 diabetes mellitus (T2DM),; Bariatric surgery; Inflammation
Issue Date: Jan-2016
Abstract: Abstract Incretins are gastrointestinal-derived hormones released in response to a meal that play a key role in the regulation of postprandial secretion of insulin (incretin effect) and glucagon by the pancreas. Both incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have several other actions. GLP-1 regulates body weight by inhibiting appetite and delaying gastric emptying, actions that are dependent on central nervous system GLP-1 receptor activation. Several other hormones and gut peptides, including leptin and ghrelin, interact with GLP-1 to modulate appetite. GLP-1 is labile, being rapidly degraded by dipeptidyl peptidase-4 (DPP-4), a multifunction molecule whose role in obesity dynamics extends beyond incretin metabolism. DPP-4 is involved in adipose tissue inflammation, which is a pivotal event in insulin resistance and a key pathophysiological mechanism in the genesis of obesity-related complications. Furthermore, the incretin system appears to provide the basis for understanding the high weight loss efficacy of bariatric surgery, a current employed obesity treatment that also benefits diabetes. The present review brings together new insights into obesity pathogenesis, integrating GLP-1 and DPP-4 in the complex interplay between obesity epidemics and inflammation, namely in diabetic patients. This will in turn provide the basis for new perspectives regarding GLP-1 receptor agonists and DPP-4 inhibitors therapeutic potential.
Description: Trabalho de revisão do 6º ano médico com vista á atribuição do grau de mestre (área científica de farmacologia) no âmbito do ciclo de estudos de Mestrado Integrado em Medicina.
URI: http://hdl.handle.net/10316/33276
Rights: openAccess
Appears in Collections:FMUC Medicina - Teses de Mestrado
UC - Dissertações de Mestrado

Files in This Item:
File Description SizeFormat
Ana Luísa João FMUC 2016.pdfAna Luísa João FMUC 20161.05 MBAdobe PDFView/Open
Show full item record

Page view(s) 20

567
checked on Nov 21, 2022

Download(s) 50

230
checked on Nov 21, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.